Fineotex Chemical Q1 FY27 Consolidated Income ₹386.72 Cr, PAT ₹48.21 Cr

CHEMICALS
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Fineotex Chemical Q1 FY27 Consolidated Income ₹386.72 Cr, PAT ₹48.21 Cr

Fineotex Chemical reported robust Q1 FY27 results with consolidated total income at ₹386.72 crore and PAT at ₹48.21 crore. The company saw significant volume growth, but investors should note reliance on unreviewed subsidiary financials and an ongoing property legal dispute.

Detailed Coverage

Fineotex Chemical Reports Strong Q1 FY27 Performance

Fineotex Chemical's consolidated total income reached ₹386.72 crore for the quarter ended June 30, 2026, with consolidated Profit After Tax (PAT) at ₹48.21 crore. The company also reported consolidated operational EBITDA of ₹59.14 crore and a significant year-over-year consolidated volume growth of 130.84%. Return on Invested Capital (ROIC) stood at a strong 33.06%.

Standalone total income was ₹95.93 crore, and standalone PAT was ₹20.53 crore during the same period.

Reader Takeaway: Robust volume growth fuels strong top and bottom lines, but unreviewed subsidiary data and a property dispute pose risks.

What just happened

Fineotex Chemical announced its financial results for the first quarter of fiscal year 2027. The company posted a consolidated total income of ₹386.72 crore and a consolidated PAT of ₹48.21 crore. A key highlight was the consolidated volume growth of 130.84% year-over-year.

Why this matters

The strong growth indicates successful scaling of operations and effective market penetration. The high ROIC of 33.06% suggests efficient use of capital to generate profits. However, the reliance on interim, unreviewed financial data from subsidiaries for a significant portion of consolidated results and an unresolved property-related legal dispute are points of caution for investors.

The backstory

The company's operations involve multiple subsidiaries, contributing substantially to the consolidated figures. Fineotex Chemical operates in the specialty chemical sector, catering to various industries.

What changes now

Investors will be looking for continued strong performance in subsequent quarters. The resolution of the legal dispute concerning the property sale and the future review status of subsidiary financials will be critical watch points.

Risks to watch

Significant portions of the consolidated revenue (₹310.83 crore) and profit (₹27.68 crore) are based on interim financial information from 13 subsidiaries that have not been reviewed or audited. Additionally, a legal dispute over a property, where the company has made payments and received an advance, remains unsettled and impacts the recognition of the sale.

Peer comparison

(No peer comparison data available in the filing).

Context metrics (time-bound)

Consolidated Total Income (Q1 FY27): ₹386.72 crore
Consolidated PAT (Q1 FY27): ₹48.21 crore
Consolidated Volume Growth (YoY): 130.84%
Consolidated ROIC (Q1 FY27): 33.06%
Standalone Total Income (Q1 FY27): ₹95.93 crore
Standalone PAT (Q1 FY27): ₹20.53 crore

What to track next

Investors should monitor future quarterly results for sustained volume growth and profitability. Particular attention should be paid to the status of the subsidiary financial reviews and the outcome of the property legal dispute.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.